News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

News

Article

April 5, 2024

Nevada Health Link Announces AI Implementation

Author(s):

Mike Hollan

The technology will reportedly improve consumer engagement.

stock.adobe.com

Stock.adobe.com

AI is going to Nevada.

Nevada Health Link announced that it is implementing AI onto its State-Based Marketplace platform (SBM). In a press release,1 the health insurance marketplace stated that it is the first SBM to be approved to use AI technology for Centers for Medicare and Medicaid Services approval.

GetInsured, a technology provider for SBMs, developed the AI technology. Customers accessing the site will be able to utilize AI-powered virtual agents for customer service. According to the press release, GetInsured worked closely with the state to ensure that the technology met the highest standards for privacy and security.

Tim Galluzi is the state chief information officer at the Office of the Chief Information Officer (OCIO). In a press release, he said, “The successful integration of AI into Nevada Health Link, facilitated through collaboration with GetInsured, showcases Nevada's commitment to employing cutting-edge technology to serve its residents more effectively. At the OCIO, we applaud all our partner agencies advancing the technology that impacts service delivery to Nevadans and this initiative highlights ongoing pursuit of excellence in leveraging technology to meet the evolving needs of Nevadans."

In the same press release, Nevada Health Link’s executive director Russell Cook said, “Given the prevalence of gig workers and individuals with unconventional work schedules in Nevada's diverse workforce, the integration of AI into the Nevada Health Link platform ensures that essential support is available round-the-clock.”

He continued, “This cutting-edge technology caters to their needs, offering seamless assistance to individuals seeking information or help at any hour. The AI technology increases the call center capacity by streamlining consumer interactions, reducing peak call volumes, and allowing Customer Service Representatives to focus on complex queries."

According to GetInsured, the virtual agent service was available during the 2024 open enrollment period. During this time period, about 14.5% of the state’s calls were handled by the AI virtual agents. The agents were able to handle basic tasks, such as resetting passwords, unlocking accounts, and uploading documents, which left human workers available for more complex needs.

"Our relationship with Nevada Health Link began when we transitioned it off of the federal marketplace, HealthCare.gov, in 2019 and has grown over the years," said Chini Krishnan, Founder and CEO at GetInsured. "The incorporation of AI stands as a testament to our strong teamwork and Nevada's resolute dedication to providing cost-effective solutions, enriching consumer interactions, and amplifying state oversight over health care initiatives.

Source

  1. Nevada Health Link Spearheads AI Implementation, Championing Cutting-Edge Technology for Unparalleled Consumer Engagement. GetInsured. April 3, 2024. https://www.prnewswire.com/news-releases/nevada-health-link-spearheads-ai-implementation-championing-cutting-edge-technology-for-unparalleled-consumer-engagement-302106461.html

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 23rd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 23rd 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 23rd 2025

Lighthouse Pharmaceuticals Awarded $49.2 Million Grant from NIA to Advance Phase 2 study of LHP588

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 23rd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
© WESTOCK - © WESTOCK - stock.adobe.com
August 23rd 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 23rd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor
Related Content
Advertisement
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 23rd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 23rd 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 23rd 2025

Lighthouse Pharmaceuticals Awarded $49.2 Million Grant from NIA to Advance Phase 2 study of LHP588

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 23rd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
© WESTOCK - © WESTOCK - stock.adobe.com
August 23rd 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 23rd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.